If you have been reading about GHK-Cu and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide was isolated from human plasma in the early 1970s by Loren Pickart, who observed that a plasma fraction from young donors stimulated growth in cultured liver cells. The copper-bound form is abbreviated GHK-Cu, while the metal-free peptide is written simply as GHK. In the research literature the complex also appears as copper tripeptide-1 and as glycyl-histidyl-lysine copper complex.
Copper(II) binds the peptide through four nitrogen donors: the terminal amino group, the imidazole nitrogen of histidine, and two deprotonated amide nitrogens of the peptide backbone. This tetradentate arrangement gives a roughly square-planar geometry, the thermodynamically favoured form near neutral pH. Because the amide nitrogens must lose a proton before they can coordinate, complex formation is strongly pH-dependent, and the fully coordinated species dominates only above mildly acidic conditions. Electronic transitions within the copper d orbital set produce the characteristic blue to violet colour in aqueous solution.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Anatomically embalmed cadavers have a typically uniform grey colouration, due both to the high formaldehyde concentration mixed with the blood and the lack of red colouration agents commonly added to standard, nonmedical, embalming fluids. Formaldehyde mixed with blood causes the grey discoloration also known as "formaldehyde grey" or "embalmer's grey". A new embalming technique developed gradually since the 1960s by anatomist Walter Thiel at the Graz Anatomy Institute in Austria has been the subject of various academic papers, as the cadaver retains the body's natural color, texture and plasticity after the process. The method uses 4-chloro-3-methylphenol and various salts for fixation, boric acid for disinfection, and ethylene glycol for the preservation of tissue plasticity. The embalmed cadavers are used in anatomical research, surgical and anaesthesia training, preoperative test procedures, CT image quality studies.
=== Environmental exposure === Formaldehyde and its adducts are ubiquitous in nature. Food may contain formaldehyde at levels 1–100 mg/kg. Formaldehyde, formed in the metabolism of the amino acids serine and threonine, is found in the bloodstream of humans and other primates at concentrations of approximately 50 micromolar. Even in animals that were deliberately exposed to formaldehyde, most formaldehyde-DNA adducts found in non-respiratory tissues derive from endogenously produced formaldehyde. Formaldehyde does not accumulate in the environment. It is broken down within a few hours by sunlight or by bacteria in soil or water. Humans metabolize formaldehyde quickly, converting it to formic acid. It nonetheless presents significant health concerns as a contaminant.
Soybean meal, or soymeal, is the material remaining after solvent extraction of oil from soybean flakes, with a 50% soy protein content. The meal is 'toasted' (a misnomer because the heat treatment is with moist steam) and ground in a hammer mill. Ninety-seven percent of soybean meal production globally is used as livestock feed. Soybean meal is also used in some dog foods.
Sources: en.wikipedia.org
A number of these women would go on to join a class action lawsuit, Madrigal v. Quilligan, discussed below. These Mexican and Mexican-American women were given the stereotype as "hyper-fertile" and were believed to lack the knowledge of birth control methods due to the high numbers of teen pregnancies occurring within their community. At the Hospital of LA County+USC, coercive sterilization was justified as it was an attempt to control the birthrate of these women. In 1998 the US government performed a census and multiyear analysis of Latino births and found the women of Mexican origin displayed the highest rate of childbirth compared to other Latina women. From these statistics, the "Save our State" campaign arose and worked to enforce more eugenic sterilization of these women. In 1973 an investigation by progressive anti-sterilization advocacy groups discovered the stories of Mary Alice's and Minnie Lee Relf's sterilization. This story was released by the Southern Poverty Law Center and led to the discovery of 16 thousand women and 8,000 men being sterilized using federal funds in 1972. In addition to this finding, they found more than three hundred of these patients were under the legal age of 21. Following this discovery and exposure, in 1977 Mexican-American began coming forth to file lawsuits in relation to coercive sterilization they faced while in labor. In 1979 a bill to repeal the eugenics laws passed that legalized sterilization was proposed to the legislature in California.
Although membrane permeability changes are less common as a mechanism of resistance, studies investigating Klebsiella pneumoniae have reported a correlation between decreased permeability of piperacillin and increased SHV-1 β-lactamase production.
=== Allegations of steroid use and National Baseball Hall of Fame === Bagwell was eligible for induction into the Baseball Hall of Fame for the first time in 2011. Speculation abounded that some baseball writers initially refrained from voting for Bagwell on the premise that he used performance-enhancing drugs, since most of his playing career took place during what is commonly referred to as "the steroid era." In spite of the speculation, as of 2016, no concrete evidence has surfaced linking him to the use of performance-enhancing drugs. However, one report indicates that he disclosed use of androstenedione to a Houston Chronicle reporter in 1998. At that time, neither the FDA nor MLB had banned its use. Bagwell has not been connected with any of the 104 positive samples in the 2003 survey tests that were leaked. Bagwell was not among the 89 players named in the Mitchell Report released in 2007. Longtime Atlanta Braves manager Bobby Cox said the following about Bagwell: "Jeff Bagwell was [in Houston] for so long and starred every year. For me a guy that dominated like that for one team, even in the league stats through the years. His are up there with anybody's. I would put him in right away. So he would get my vote on the first ballot." Still, in spite of the speculation that Bagwell used performance-enhancing drugs, San Francisco Chronicle sportswriter Bruce Jenkins wrote that Bagwell did not have the credentials to be in the Hall of Fame. In July 2015, he acknowledged "that many are suspicious of Bagwell—without proof, as you say.
Sources: en.wikipedia.org
After the conclusion of the visit, Trump posted on Truth Social, where he confirmed the two leaders would meet again at the APEC China 2026 in Shenzhen in November and the 2026 G20 Miami summit in December. He said "Much has been, and will be, accomplished. I look forward to our next meeting!" On September 26, the government of China announced that the leaders of China and the United States reached an eight-point consensus, including:
After many and long negotiations, the companies came to the agreement to compensate Coulter for the sales that had been made in USA and some European countries where he had the patent and that AB Lars Ljungberg & Co was free to sell their analyzer in other regions.
=== Interactions between biomolecules === Coimmunoprecipitation Electrophoretic mobility shift assay Southwestern blotting Isothermal titration calorimetry Fluorescence anisotropy Microscale thermophoresis
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
It consists of a three-amino-acid peptide, glycine-histidine-lysine, bound to one copper(II) ion. The peptide supplies four nitrogen donor atoms, and the resulting complex is stable in neutral aqueous solution. The metal-free peptide is usually called GHK.